Roche Holding AG
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT04313608
- Locations
- π¦πΊ
Prince of Wales Hospital; Haematology, Randwick, New South Wales, Australia
π¦πΊMonash Health Monash Medical Centre, Clayton, Victoria, Australia
π¦πΊSt Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT04308785
- Locations
- π¨π³
Anhui Province Cancer Hospital, Hefei City, China
π¨π³Guangxi Cancer Hospital of Guangxi Medical University, Nanning, China
π¨π³Tianjin Cancer Hospital, Tianjin, China
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 189
- Registration Number
- NCT04303858
- Locations
- πͺπΈ
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
π§πͺUZ Leuven Gasthuisberg, Leuven, Belgium
πͺπΈVall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain
A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 172
- Registration Number
- NCT04300647
- Locations
- πΊπΈ
Kaiser Permanente - Irvine, Irvine, California, United States
πΊπΈOncology Associates of Oregon, P.C, Eugene, Oregon, United States
π¦πΊMater Misericordiae Limited, South Brisbane, Queensland, Australia
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 103
- Registration Number
- NCT04299464
- Locations
- πΊπΈ
Southwest Autism Research and Resource Center, Phoenix, Arizona, United States
πΊπΈUPMC Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States
πΊπΈNathan Kline Institute, Orangeburg, New York, United States
A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT04298918
- Locations
- π¦πΊ
Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
π°π·Asan Medical Center, Seoul, Korea, Republic of
π°π·Samsung Medical Center, Seoul, Korea, Republic of
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 620
- Registration Number
- NCT04294810
- Locations
- πΊπΈ
US oncology research at Minnesota Oncology, Saint Paul, Minnesota, United States
πΊπΈOnc & Hem Assoc SW Virginia, Salem, Virginia, United States
π¦πΊAustin Hospital Olivia Newton John Cancer Centre, Heidelberg, Victoria, Australia
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 166
- Registration Number
- NCT04285567
- Locations
- π«π·
CHU de Caen, Institut d'HΓ©matologie de Basse-Normandie, Caen, France
π«π·Hopital Robert Debre; Hematologie Clinique, Reims, France
πΊπΈOncology & Hematolgy Associates of SW Va Inc. - Roanoke, Roanoke, Virginia, United States
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04267237
A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT04265261
- Locations
- πΊπΈ
Rand Eye, Deerfield Beach, Florida, United States
πΊπΈRetina Associates Tucson, Tucson, Arizona, United States
πΊπΈUniversity of Michigan, Kellogg Eye Center, Ann Arbor, Michigan, United States